Exploiting the promiscuity of imatinib

Journal of Biology

Volumn 8, Issue 3, 2009, Pages

  Lee, Shun J ^a,b   Wang, Jean Y J ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BCR ABL PROTEIN; IMATINIB; KIT TYROSINE KINASE; NQO 2 PROTEIN; OXIDOREDUCTASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; NRH - QUINONE OXIDOREDUCTASE2; NRH QUINONE OXIDOREDUCTASE2; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

BONE MARROW TOXICITY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CROHN DISEASE; CRYSTAL STRUCTURE; DIARRHEA; DRUG BINDING; DRUG CONFORMATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; EDEMA; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MUSCLE CRAMP; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; SPONDYLARTHRITIS; ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; ENZYME SPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR STRUCTURE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINONE REDUCTASES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 69049092008     PISSN: None     EISSN: 14754924     Source Type: Journal    
DOI: 10.1186/jbiol134     Document Type: Short Survey

References (10)

1. Translation of the Philadelphia chromosome into therapy for CML. BJ Druker, Blood 2008 112 4808 4817 10.1182/blood-2008-07-077958 19064740
2. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. U Rix O Hantschel G Durnberger LL Remsing Rix M Planyavsky NV Fernbach I Kaupe KL Bennett P Valent J Colinge T Kocher G Superti-Furga, Blood 2007 110 4055 4063 10.1182/blood-2007-07-102061 17720881
3. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. M Bantscheff D Eberhard Y Abraham S Bastuck M Boesche S Hobson T Mathieson J Perrin M Raida C Rau V Reader G Sweetman A Bauer T Bouwmeester C Hopf U Kruse G Neubauer N Ramsden J Rick B Kuster G Drewes, Nat Biotechnol 2007 25 1035 1044 10.1038/nbt1328 17721511
4. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. MJ Eck PW Manley, Curr Opin Cell Biol 2009 doi:10.1016/j.ceb.2009.01.014. 19217274
5. Genome-Wide Identification of Genes Required for Yeast Growth Under Imatinib Stress: Vacuolar H(+)-ATPase Function Is an Important Target of This Anticancer Drug. SC Santos I Sa-Correia, Omics 2009 19260806
6. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). JA Winger O Hantschel G Superti-Furga J Kuriyan, BMC Struct Biol 2009 9 7 19236722 10.1186/1472-6807-9-7
7. Imatinib as a novel therapeutic approach for fibrotic disorders. JH Distler O Distler, Rheumatology 2009 48 2 4 10.1093/rheumatology/ken431 19029132
8. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. EJ Su L Fredriksson M Geyer E Folestad J Cale J Andrae Y Gao K Pietras K Mann M Yepes DK Strickland C Betsholtz U Eriksson DA Lawrence, Nat Med 2008 14 731 737 10.1038/nm1787 18568034
9. Tyrosine kinase inhibitors reverse type 1diabetes in nonobese diabetic mice. C Louvet GL Szot J Lang MR Lee N Martinier G Bollag S Zhu A Weiss JA Bluestone, Proc Natl Acad Sci USA 2008 105 18895 18900 10.1073/pnas.0810246105 19015530
10. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. T Force DS Krause RA Van Etten, Nat Rev Cancer 2007 7 332 344 10.1038/nrc2106 17457301